Beretta Holding Escalates Proxy Fight, Citing Ruger's "Urgent Need for Boardroom Change"
RGR sits 39% above its 52-week low of $28.33.
Summary
Activist investor Beretta Holding S.A. launched a new offensive in its proxy fight for Sturm, Ruger & Co., sending a letter to shareholders detailing the company's operational failures and advocating for immediate board changes.
Key Events · Ownership and Investor Activity · RGR
-
Proxy Solicitation Launched
Beretta Holding S.A. sent a letter and issued a press release to Sturm, Ruger & Co. shareholders, initiating a proxy solicitation for its slate of four independent director nominees at the upcoming 2026 Annual Meeting.
-
Accusations of Underperformance
Beretta highlighted "sustained share price underperformance" and "rapid operational deterioration," including 23% gross margin compression, 30% operating margin compression, and a 103% net income decline since 2021.
-
Board Alignment Concerns
The activist investor criticized the current long-tenured directors for owning only about 1% of shares, suggesting a lack of alignment with shareholder interests.
-
Call for Boardroom Change
Beretta asserts that shareholder-driven change is urgently needed to "Reload Ruger" and restore value, emphasizing that they are not seeking control but rather improved performance.
Analysis · RGR · Manufacturing
This filing from activist investor Beretta Holding S.A. intensifies the ongoing proxy battle for Sturm, Ruger & Co. Beretta, the largest shareholder, is directly appealing to shareholders, detailing severe operational deterioration and sustained share price underperformance under the current board. The accusations of 23% gross margin compression, 30% operating margin compression, and a 103% net income decline since 2021 highlight significant challenges. This move signals a critical juncture for the company, as shareholders will need to decide between the incumbent board and Beretta's proposed slate of directors, potentially leading to substantial strategic and leadership changes, especially given the company's recent net loss and adoption of a poison pill.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1144 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGR was trading at $39.45 on NYSE in the Manufacturing sector, with a market capitalization of approximately $629M. The 52-week trading range was $28.33 to $48.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.